Results 21 to 30 of about 216,694 (240)

Multiple Sclerosis Relapsing Remitting Progressive Type

Jurnal Profesi Medika, 2020
Multiple sclerosis (MS) is the most common neurologic demyelinating disease in high-income countries. The causes of MS is multifactorial involve genetics and the environment in which immune cell infiltration occurs across the blood-brain barrier, causing
Nora Fitri, Basjiruddin Ahmad, Yuliarni Syafrita   +2 more
doaj   +1 more source

Modern Technology in Multi-Shell Diffusion MRI Reveals Diffuse White Matter Changes in Young Adults With Relapsing-Remitting Multiple Sclerosis

Frontiers in Neuroscience, 2021
ObjectiveTo characterize microstructural white matter changes related to relapsing-remitting multiple sclerosis using advanced diffusion MRI modeling and tractography.
Ann-Marie Beaudoin, François Rheault, Guillaume Theaud, Frédéric Laberge, Kevin Whittingstall, Albert Lamontagne, Maxime Descoteaux   +6 more
doaj   +1 more source

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

CNS Drugs, 2020
Background Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF).
R. Naismith, A. Wundes, T. Ziemssen, Elżbieta Jasińska, M. Freedman, A. Lembo, K. Selmaj, I. Bidollari, Hailu Chen, J. Hanna, Richard A Leigh-Pemberton, M. Lopez-Bresnahan, Jennifer Lyons, Catherine Miller, David Rezendes, J. Wolinsky   +15 more
semanticscholar   +1 more source

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Neurology, 2020
OBJECTIVE To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis, we modelled disability outcomes in 14,717 patients.
T. Kalincik, I. Diouf, S. Sharmin, C. Malpas, T. Spelman, D. Horáková, E. Havrdová, M. Trojano, G. Izquierdo, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, V. Jokubaitis, A. van der Walt, F. Grand'Maison, P. Sola, D. Ferraro, V. Shaygannejad, R. Alroughani, R. Hupperts, M. Terzi, C. Boz, J. Lechner-Scott, E. Pucci, V. van Pesch, F. Granella, R. Bergamaschi, D. Spitaleri, M. Slee, S. Vucic, R. Ampapa, P. Mccombe, C. Ramo-Tello, J. Prevost, J. Olascoaga, E. Cristiano, M. Barnett, M. Saladino, J. Sánchez-Menoyo, S. Hodgkinson, C. Rózsa, S. Hughes, F. Moore, C. Shaw, E. Butler, O. Skibina, O. Gray, A. Kermode, T. Csépány, B. Singhal, N. Shuey, Imre Piroska, B. Taylor, M. Simó, C. Sîrbu, A. Sas, H. Butzkueven   +58 more
semanticscholar   +1 more source

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

Italian Journal of Pediatrics, 2021
Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women ...
Elisabetta Godano, Fabio Barra, Alessandra Allodi, Antonella Ferraiolo, Alice Laroni, Giovanni Novi, Giovanni Luigi Mancardi, Claudio Gustavino, Cesare Arioni   +8 more
doaj   +1 more source

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Multiple Sclerosis, 2018
Background: In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing–remitting multiple sclerosis (MS).
G. Giovannoni, P. Soelberg Sørensen, S. Cook, K. Rammohan, P. Rieckmann, G. Comi, F. Dangond, Abidemi K. Adeniji, P. Vermersch   +8 more
semanticscholar   +1 more source

Prevalence of sexual disorders in relapsing-remitting multiple sclerosis patients depending on various risk factors [PDF]

Romanian Journal of Medical Practice
Objective. Multiple sclerosis is a perilous, disabling, physically as well as mentally, demyelinating disease of the central nervous system. This work aims to evaluate prevalence of sexual dysfunctions and their correspondence with non- and disease ...
Tetiana Odintsova, Oksana Kopchak
doaj   +1 more source

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

Journal of the American Medical Association (JAMA), 2019
Importance Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).
R. Burt, R. Balabanov, J. Burman, B. Sharrack, J. Snowden, M. Oliveira, J. Fagius, J. Rose, F. Nelson, A. Barreira, K. Carlson, Xiaoqiang Han, D. Moraes, A. Morgan, Kathleen Quigley, Kim Yaung, R. Buckley, C. Alldredge, Allison M. Clendenan, Michelle A. Calvario, Jacquelyn Henry, B. Jovanovic, I. Helenowski   +22 more
semanticscholar   +1 more source

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Sarah L Minden, R Philip Kinkel, Helene T Machado, Jonathan S Levin, Meredith B Rosenthal, Lisa I Iezzoni   +5 more
doaj   +1 more source

Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis

Arquivos de Neuro-Psiquiatria, 2011
Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests ...
Dóra-Neide Rodrigues, Renata Alves Paes, Claudia Cristina Ferreira Vasconcelos, Jesus Landeira-Fernandez, Maria Papais Alvarenga   +4 more
doaj   +1 more source